Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis

Keyphrases

• Fatty Acid Metabolism 100%
• Disease Activity 100%
• Multiple Sclerosis 100%
• Inflammation 50%
• Carnitine Palmitoyltransferase 1A (CPT1A) 50%
• Inflammatory Cytokines 25%
• Apoptosis 25%
• Effective Treatment 25%
• Disease Severity 25%
• Demyelination 25%
• Metabolism 25%
• Autoimmunity 25%
• Cytokine Production 25%
• Immune Cells 25%
• Disease Course 25%
• Neurological Impairment 25%
• Experimental Autoimmune Encephalomyelitis 25%
• Rate-limiting Enzyme 25%
• Putative Drug Targets 25%
• Immunopathology 25%
• Central Nervous System Demyelinating Diseases 25%
• Fatty Acid β-oxidation 25%
• Mouse Model of multiple Sclerosis 25%
• Demyelinating Disease 25%
• Metabolic Pathways 25%
• Pathogenic T Cells 25%

Immunology and Microbiology

• Fatty Acid Metabolism 100%
• Multiple Sclerosis 100%
• Inflammation 40%
• Mouse Model 20%
• T Cell 20%
• Immunocompetent Cell 20%
• Downregulation 20%
• Autoimmunity 20%
• Central Nervous System 20%
• Metabolism 20%
• Cytokine Production 20%
• Clinically Isolated Syndrome 20%
• Experimental Autoimmune Encephalomyelitis 20%
• Inflammatory Cytokine 20%
• Fatty Acid Oxidation 20%
• Immunopathology 20%
• Programmed Cell Death 20%
• Fatty Acid 20%
• Therapeutic Target 20%